1. Home
  2. KXIN vs SNOA Comparison

KXIN vs SNOA Comparison

Compare KXIN & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KXIN

Kaixin Auto Holdings

HOLD

Current Price

$5.30

Market Cap

7.0M

ML Signal

HOLD

Logo Sonoma Pharmaceuticals Inc.

SNOA

Sonoma Pharmaceuticals Inc.

HOLD

Current Price

$1.14

Market Cap

5.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KXIN
SNOA
Founded
2015
1999
Country
China
United States
Employees
13
N/A
Industry
Retail-Auto Dealers and Gas Stations
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.0M
5.8M
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
KXIN
SNOA
Price
$5.30
$1.14
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
60.1K
74.0K
Earning Date
11-26-2019
06-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.26
EPS
N/A
N/A
Revenue
N/A
$19,529,000.00
Revenue This Year
N/A
$23.00
Revenue Next Year
N/A
$24.59
P/E Ratio
N/A
N/A
Revenue Growth
N/A
36.68
52 Week Low
$0.11
$0.85
52 Week High
$22.00
$6.92

Technical Indicators

Market Signals
Indicator
KXIN
SNOA
Relative Strength Index (RSI) 54.77 39.77
Support Level $5.30 $1.02
Resistance Level $6.09 $1.25
Average True Range (ATR) 0.60 0.06
MACD 0.09 -0.01
Stochastic Oscillator 64.21 14.95

Price Performance

Historical Comparison
KXIN
SNOA

About KXIN Kaixin Auto Holdings

Kaixin Holdings is an auto dealership company mainly engaged in the sale of domestic and imported automobiles in China. The company provides new and used car buyers in China with access to a wide selection of used vehicles across its network of dealerships, with a focus on premium brands such as Audi, BMW, Mercedes-Benz, Land Rover, and Porsche. The company generates revenue from automobile sales and related services.

About SNOA Sonoma Pharmaceuticals Inc.

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.

Share on Social Networks: